Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Communications
Publications
Investor Presentations
In the News
Posters
Publications
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Categories
Company News
Media
Uncategorized
Videos
26 Apr 2023
Quarterly Activities and Cash Flow Report - 31 March 2023
Read More
19 Apr 2023
First Patient Recruited to Cohort 3 of ACCENT Trial in Pancreatic Cancer
Read More
11 Apr 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
1